Progress Revealed At Enzon
Enzon executives speaking at the firm's annual meeting for shareholders said that the US biopharmaceutical company has improved its burn rate and cash balance, which is now sufficient for two years.
In October, the company secured Medac GmbH, a German pharmaceutical company, to market Oncaspar (L-asparaginase) in Europe and Russia. Medac will conduct clinical trials for new indications, such as first-line therapy of acute lymphoblastic leukemia, adult ALL, non-Hodgkin's lymphoma and AIDS-related lymphoma, as well as obtain registrations for the remaining countries where the product is not yet approved.
In an alliance with Japanese company Green Cross for development of recombinant human serum albumin, the product is in Phase III clinical trials in Japan as a blood volume expander.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze